Hooker, Moellenhoff et al. are moving MBBE forward [BE/BA News]

posted by mittyri – Russia, 2023-01-11 16:32 (27 d 08:26 ago) – Posting: # 23421
Views: 747

Hi Helmut and all!

just want to share model based approaches FDA is working on with different scentists.
Uppsala Universitet raises the flag:
Hooker #1
Hooker #2
He claims that model averaging should help in case of troubles with model building.

Kathrin Moellenhof with colleagues (another giant there: France Mentre) are attacking classical BE approaches from other side.
Interesting results of TIE estimation. Simulation-based only.

In PubMed you can see multiple papers referencing this article.

Kind regards,
Mittyri

Complete thread:

UA Flag
Activity
 Admin contact
22,485 posts in 4,710 threads, 1,603 registered users;
18 visitors (0 registered, 18 guests [including 11 identified bots]).
Forum time: 00:58 CET (Europe/Vienna)

The difference between a surrogate and a true endpoint
is like the difference between a cheque and cash.
You can get the cheque earlier but then,
of course, it might bounce.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5